Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation

Pediatric Transplantation

Volumn 19, Issue 6, 2015, Pages 652-658

  Inagaki, Jiro ^a   Kodama, Yuichi ^a   Fukano, Reiji ^a   Noguchi, Maiko ^a   Okamura, Jun ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

children; hematopoietic stem cell transplantation; mycophenolate mofetil; steroid refractory acute GVHD

Indexed keywords

FOSCARNET SODIUM; GANCICLOVIR; MYCOPHENOLATE MOFETIL; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BK VIRUS INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HUMAN; INFANT; INVASIVE ASPERGILLOSIS; MALE; NEUTROPENIA; NEWBORN; PRESCHOOL CHILD; REMISSION; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL GASTROENTERITIS; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; EVALUATION STUDY; GRAFT VS HOST DISEASE; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; MALE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84938210344     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12545     Document Type: Article

References (23)

1. Macmillan ML, Weisdorf DJ, Wagner JE, et al., Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002: 8: 387-394.
2. Weisdorf D, Haake R, Blazar B, et al., Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 1990: 75: 1024-1030.
3. Martin PJ, Schoch G, Fisher L, et al., A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990: 76: 1464-1472.
4. Deeg HJ,. How I treat refractory acute GVHD. Blood 2007: 109: 4119-4126.
5. Martin PJ, Rizzo JD, Wingard JR, et al., First- and second-line systemic treatment of acute graft-versus-host disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012: 18: 1150-1163.
6. Dignan FL, Clark A, Amrolia P, et al., Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012: 158: 30-45.
7. Xhaard A, Rocha V, Bueno B, et al., Steroid-refractory acute GVHD: Lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 2012: 18: 406-413.
8. Allison AC, Eugui EM,. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996: 10: 77-84.
9. Przepiorka D, Weisdorf D, Martin P, et al., 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995: 15: 825-828.
10. Inagaki J, Fukano R, Kodama Y, Nishimura M, Shimokawa M, Okamura J,. Safety and efficacy of low-dose methotrexate for pediatric patients with steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplantation. Ann Hematol 2014: 93: 645-651.
11. Pidala J, Kim J, Perkins J, et al., Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant 2010: 45: 919-924.
12. Alousi AM, Weisdorf DJ, Logan BR, et al.,; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: A randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009: 114: 511-517.
13. Furlong T, Martin P, Flowers ME, et al., Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009: 44: 739-748.
14. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N,. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: A series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002: 30: 287-295.
15. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J,. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005: 84: 681-685.
16. Onishi C, Ohashi K, Sawada T, et al., A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. Int J Hematol 2000: 91: 464-470.
17. Busca A, Saroglia EM, Lanino E, et al., Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000: 25: 1067-1071.
18. Nash RA, Johnston L, Parker P, et al., A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005: 11: 495-505.
19. Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, Mccune JS,. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol 2013: 53: 393-402.
20. Jacobson PA, Huang J, Wu J, et al., Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 2010: 16: 421-429.
21. Jacobson P, Rogosheske J, Barker JN, et al., Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005: 78: 486-500.
22. Jacobson P, Huang J, Rydholm N, et al., Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). J Clin Pharmacol 2008: 48: 485-494.
23. Martin PJ, Storer BE, Rowley SD, et al., Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009: 113: 5074-5082.